Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01097408Phase 1Completed

Pharmacokinetics of AZD7295 Capsules

Role: lead

NCT00781976Phase 1Completed

Antiviral Activity of AZD7295 in HCV Carriers

Role: lead

NCT00906256Phase 1Completed

Clinical Pharmacology Study of AZD7295 in Healthy Subjects

Role: lead

NCT00232635Phase 2Completed

A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT

Role: lead

NCT00522808Phase 1Terminated

A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers

Role: lead

All 5 trials loaded